pharma · Parkinson Disease · Tuberculosis · GANX
Gain Therapeutics
Gain Therapeutics patent portfolio — 27 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Bethesda, USA
- Founded
- 2017
- Employees
- 28
- Programs
- 4
- Drugs
- 7
- Patents
- 27
Gain Therapeutics patents
27 pharmaceutical patents indexed for Gain Therapeutics. 0 expire within 24 months.
Gain Therapeutics has 27 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12370232
Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition
granted -
US 12201701
Vegetable oil-derived contrast agent with high stability and preparation method thereof
granted -
US 11730178
Extraction method
granted -
US 11311581
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
granted -
US 11020365
Mixture of fatty acids for use in the treatment of inflammatory pathologies
granted -
US 10960000
Abuse resistant pharmaceutical compositions
granted -
US 10646523
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
granted -
US 10213389
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
granted -
US 10092559
Abuse resistant pharmaceutical compositions
granted -
US 10080720
Pharmaceutical composition containing docetaxel
granted -
US 9713611
Abuse resistant pharmaceutical compositions
granted -
US 9499667
Biodegradable surfactant, preparation method and use thereof
granted -
US 9486451
Abuse resistant pharmaceutical compositions
granted -
US 9463166
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
granted -
US 9452163
Abuse resistant pharmaceutical compositions
granted -
US 7601735
Antiviral compounds
granted -
US 6974594
Method of preparing biological materials and preparations produced using same
expired -
US 6610866
Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
expired -
US 6433144
Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
expired -
US 6399370
Compositions and methods for use of defensin
expired -
US 6353363
Low voltage rail-to-rail CMOS output stage
expired -
US 6350589
Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
expired -
US 6348445
Biologically active peptides with reduced toxicity in animals and a method for preparing same
expired -
US 6262283
Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
expired -
US 6147060
Treatment of carcinomas using squalamine in combination with other anti-cancer agents
expired -
US 6143738
Therapeutic uses for an aminosterol compound
expired -
US 6037149
DNA encoding human asthma associated factor 1
expired
Frequently asked questions
How many patents does Gain Therapeutics have?
27 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Gain Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.